Clinical Features and Natural History of Preadolescent Nonsyndromic Hypertrophic Cardiomyopathy

[1]  A. Shandilya,et al.  Sudden cardiac death in childhood hypertrophic cardiomyopathy. , 2023, Disease-a-month : DM.

[2]  I. Olivotto,et al.  Clinical presentation and long‐term outcomes of infantile hypertrophic cardiomyopathy: a European multicentre study , 2021, ESC heart failure.

[3]  E. Ashley,et al.  Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy , 2021, European heart journal.

[4]  E. Rosenthal,et al.  Clinical outcomes and programming strategies of implantable cardioverter-defibrillator devices in paediatric hypertrophic cardiomyopathy: a UK National Cohort Study. , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[5]  Matthew W. Martinez,et al.  2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.

[6]  S. Solomon,et al.  Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial , 2020, The Lancet.

[7]  P. Elliott,et al.  Penetrance of Hypertrophic Cardiomyopathy in Sarcomere Protein Mutation Carriers , 2020, Journal of the American College of Cardiology.

[8]  S. Colan,et al.  A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy , 2020, Circulation.

[9]  A. Corveleyn,et al.  Clinical and ECG variables to predict the outcome of genetic testing in hypertrophic cardiomyopathy. , 2020, European journal of medical genetics.

[10]  M. Holtgrewe,et al.  Targeted panel sequencing in pediatric primary cardiomyopathy supports a critical role of TNNI3 , 2019, Clinical genetics.

[11]  R. Weintraub,et al.  Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). , 2019, JAMA cardiology.

[12]  M. Lafreniere-Roula,et al.  Family screening for hypertrophic cardiomyopathy: Is it time to change practice guidelines? , 2019, European heart journal.

[13]  P. Elliott,et al.  Yield of Clinical Screening for Hypertrophic Cardiomyopathy in Child First-Degree Relatives , 2019, Circulation.

[14]  J. Kaski,et al.  Clinical presentation and survival of childhood hypertrophic cardiomyopathy: a retrospective study in United Kingdom , 2018, European Heart Journal.

[15]  William J. Bryant,et al.  2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2018, Journal of the American College of Cardiology.

[16]  S. Colan,et al.  Long-Term Outcomes of Hypertrophic Cardiomyopathy Diagnosed During Childhood: Results From a National Population-Based Study , 2018, Circulation.

[17]  L. Carrier,et al.  Gene therapy strategies in the treatment of hypertrophic cardiomyopathy , 2018, Pflügers Archiv - European Journal of Physiology.

[18]  M. Lafreniere-Roula,et al.  Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy , 2018, Clinical genetics.

[19]  A. Keren,et al.  International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM) , 2017, Circulation.

[20]  S. Colan,et al.  Relationship of Echocardiographic Z Scores Adjusted for Body Surface Area to Age, Sex, Race, and Ethnicity: The Pediatric Heart Network Normal Echocardiogram Database , 2017, Circulation. Cardiovascular imaging.

[21]  D. Katritsis.  Abstracts of the Annual Spring Meeting 2017 of the European Congenital Heart Surgeons Association, Leicester, UK, 19-20th May, 2017 , 2017, Cardiology in the Young.

[22]  William J. Bryant,et al.  2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Heart rhythm.

[23]  M. Digilio,et al.  Cardiac defects, morbidity and mortality in patients affected by RASopathies. CARNET study results. , 2017, International journal of cardiology.

[24]  Andrea Mazzanti,et al.  [2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death]. , 2015, Kardiologia polska.

[25]  J. Petryka,et al.  Predictors of Long-Term Outcome in Children with Hypertrophic Cardiomyopathy , 2015, Pediatric Cardiology.

[26]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[27]  A. Anastasakis,et al.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.

[28]  S. Colan,et al.  Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry , 2013, The Lancet.

[29]  K. Siminovitch,et al.  Toronto Hypertrophic Cardiomyopathy Genotype Score for Prediction of a Positive Genotype in Hypertrophic Cardiomyopathy , 2013, Circulation. Cardiovascular genetics.

[30]  P. Hammond,et al.  Prevalence of Sequence Variants in the RAS-Mitogen Activated Protein Kinase Signaling Pathway in Pre-Adolescent Children With Hypertrophic Cardiomyopathy , 2012, Circulation. Cardiovascular genetics.

[31]  R. Ross.  The Ross Classification for Heart Failure in Children After 25 Years: A Review and an Age-Stratified Revision , 2012, Pediatric Cardiology.

[32]  P. Elliott,et al.  Prevalence of Sarcomere Protein Gene Mutations in Preadolescent Children With Hypertrophic Cardiomyopathy , 2008, Circulation. Cardiovascular genetics.

[33]  D. Holmgren,et al.  Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. , 2008, European heart journal.

[34]  Heidi L Rehm,et al.  Shared genetic causes of cardiac hypertrophy in children and adults. , 2008, The New England journal of medicine.

[35]  S. Colan,et al.  Epidemiology and Cause-Specific Outcome of Hypertrophic Cardiomyopathy in Children: Findings From the Pediatric Cardiomyopathy Registry , 2007, Circulation.

[36]  D. Holmgren,et al.  Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly , 2005, Cardiology in the Young.

[37]  J. Carlin,et al.  Clinical Features and Outcomes of Childhood Hypertrophic Cardiomyopathy: Results From a National Population-Based Study , 2005, Circulation.

[38]  John B Carlin,et al.  The epidemiology of childhood cardiomyopathy in Australia. , 2003, The New England journal of medicine.

[39]  E John Orav,et al.  The incidence of pediatric cardiomyopathy in two regions of the United States. , 2003, The New England journal of medicine.

[40]  O. Simell,et al.  Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. , 1997, American journal of epidemiology.

[41]  B. Maron,et al.  Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. , 1986, The New England journal of medicine.

[42]  J. Stockman.  Epidemiology and Cause-Specific Outcome of Hypertrophic Cardiomyopathy in Children: Findings From the Pediatric Cardiomyopathy Registry , 2009 .